Why the study?
The optimal strategy to prevent no-reflow in STEMI patients undergoing PCI is unknown.
Does thrombectomy reduce no-reflow in patients with STEMI undergoing primary PCI?
Does thrombectomy reduce no-reflow in patients with STEMI undergoing primary PCI?
Routine thrombectomy during primary PCI for STEMI does not reduce angiographic no-reflow overall, but may be beneficial when combined with direct stenting, while no-reflow itself strongly predicts 1-year adverse clinical outcomes.
Answers are grounded in this paper and cite their sources.
Thrombectomy should not yet change practice for no-reflow in STEMI PCI; leaves open potential benefit with direct stenting for prospective trials.
BACKGROUND: The optimal strategy to prevent no-reflow in ST-elevation myocardial infarction (STEMI) patients undergoing percutaneous coronary intervention (PCI) is unknown. AIMS: We aimed to examine the effect of thrombectomy on the outcome of no-reflow in key subgroups and the adverse clinical outcomes associated with no-reflow. METHODS: We performed a post hoc analysis of the TOTAL Trial, a randomised trial of 10,732 patients comparing thrombectomy versus PCI alone. This analysis utilised the angiographic data of 1,800 randomly selected patients. RESULTS: No-reflow was diagnosed in 196 of 1,800 eligible patients (10.9%). No-reflow occurred in 95/891 (10.7%) patients randomised to thrombectomy compared with 101/909 (11.1%) in the PCI-alone arm (odds ratio [OR] 0.95, 95% confidence interval [CI]: 0.71-1.28; p-value=0.76). In the subgroup of patients who underwent direct stenting, those randomised to thrombectomy compared with PCI alone experienced less no-reflow (19/371 [5.1%] vs 21/216 [9.7%], OR 0.50, 95% CI: 0.26-0.96). In patients who did not undergo direct stenting, there was no difference between the groups (64/504 [12.7%] vs 75/686 [10.9%)], OR 1.18, 95% CI: 0.82-1.69; interaction p-value=0.02). No-reflow patients had a significantly increased risk of experiencing the primary composite outcome (cardiovascular death, recurrent myocardial infarction, cardiogenic shock, or NYHA Class IV heart failure) at 1 year (adjusted hazard ratio 1.70, 95% CI: 1.13-2.56; p-value=0.01). CONCLUSIONS: In patients with STEMI treated by PCI, thrombectomy did not reduce no-reflow in all patients but may be synergistic with direct stenting. No-reflow is associated with increased adverse clinical outcomes.
No takes yet. Share an insight, caveat, or question.
d’Entremont et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: